Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

News Feature

A call to arms


Widespread resistance to our arsenal of antibiotics is no longer a threat — it is reality. With no new antibacterial drugs expected to reach the market any time soon, immediate action is needed to avert a looming healthcare disaster. But antibacterial discovery faces immense scientific and business challenges. What needs to be done to turn the tide? As part of this special Focus issue on Antibacterials, Nature Reviews Drug Discovery asked representatives from industry, academia, the FDA and the clinic working on different aspects of antibacterial research to give their own perspectives on where the next generation of antibiotics will come from.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Rights and permissions

Reprints and Permissions

About this article

Cite this article

A call to arms. Nat Rev Drug Discov 6, 8–12 (2007).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing